Discovery - University of Dundee - Online Publications

Library & Learning Centre

Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma

Standard

Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma : Relationship to disease severity. / Chaudhuri, Rekha; McSharry, Charles; Brady, Jeffrey; Donnelly, Iona; Grierson, Christal; McGuinness, Stephen; Jolly, Lisa; Weir, Christopher J.; Messow, C. Martina; Spears, Mark; Miele, Gino; Nocka, Karl; Crowther, Dan; Thompson, Joyce; Brannigan, Maureen; Lafferty, Jane; Sproule, Michael; MacNee, William; Connell, Martin; Murchison, John T.; Shepherd, Malcolm C.; Feuerstein, Giora; Miller, Douglas K.; Thomson, Neil C.

In: Journal of Allergy and Clinical Immunology, Vol. 129, No. 3, 03.2012, p. 655-U106.

Research output: Contribution to journalArticle

Harvard

Chaudhuri, R, McSharry, C, Brady, J, Donnelly, I, Grierson, C, McGuinness, S, Jolly, L, Weir, CJ, Messow, CM, Spears, M, Miele, G, Nocka, K, Crowther, D, Thompson, J, Brannigan, M, Lafferty, J, Sproule, M, MacNee, W, Connell, M, Murchison, JT, Shepherd, MC, Feuerstein, G, Miller, DK & Thomson, NC 2012, 'Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma: Relationship to disease severity' Journal of Allergy and Clinical Immunology, vol 129, no. 3, pp. 655-U106., 10.1016/j.jaci.2011.12.996

APA

Chaudhuri, R., McSharry, C., Brady, J., Donnelly, I., Grierson, C., McGuinness, S., ... Thomson, N. C. (2012). Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma: Relationship to disease severity. Journal of Allergy and Clinical Immunology, 129(3), 655-U106. 10.1016/j.jaci.2011.12.996

Vancouver

Chaudhuri R, McSharry C, Brady J, Donnelly I, Grierson C, McGuinness S et al. Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma: Relationship to disease severity. Journal of Allergy and Clinical Immunology. 2012 Mar;129(3):655-U106. Available from: 10.1016/j.jaci.2011.12.996

Author

Chaudhuri, Rekha; McSharry, Charles; Brady, Jeffrey; Donnelly, Iona; Grierson, Christal; McGuinness, Stephen; Jolly, Lisa; Weir, Christopher J.; Messow, C. Martina; Spears, Mark; Miele, Gino; Nocka, Karl; Crowther, Dan; Thompson, Joyce; Brannigan, Maureen; Lafferty, Jane; Sproule, Michael; MacNee, William; Connell, Martin; Murchison, John T.; Shepherd, Malcolm C.; Feuerstein, Giora; Miller, Douglas K.; Thomson, Neil C. / Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma : Relationship to disease severity.

In: Journal of Allergy and Clinical Immunology, Vol. 129, No. 3, 03.2012, p. 655-U106.

Research output: Contribution to journalArticle

Bibtex - Download

@article{ecc5cf1354e9481687411919781a25d0,
title = "Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma: Relationship to disease severity",
author = "Rekha Chaudhuri and Charles McSharry and Jeffrey Brady and Iona Donnelly and Christal Grierson and Stephen McGuinness and Lisa Jolly and Weir, {Christopher J.} and Messow, {C. Martina} and Mark Spears and Gino Miele and Karl Nocka and Dan Crowther and Joyce Thompson and Maureen Brannigan and Jane Lafferty and Michael Sproule and William MacNee and Martin Connell and Murchison, {John T.} and Shepherd, {Malcolm C.} and Giora Feuerstein and Miller, {Douglas K.} and Thomson, {Neil C.}",
year = "2012",
doi = "10.1016/j.jaci.2011.12.996",
volume = "129",
number = "3",
pages = "655--U106",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma

T2 - Relationship to disease severity

A1 - Chaudhuri,Rekha

A1 - McSharry,Charles

A1 - Brady,Jeffrey

A1 - Donnelly,Iona

A1 - Grierson,Christal

A1 - McGuinness,Stephen

A1 - Jolly,Lisa

A1 - Weir,Christopher J.

A1 - Messow,C. Martina

A1 - Spears,Mark

A1 - Miele,Gino

A1 - Nocka,Karl

A1 - Crowther,Dan

A1 - Thompson,Joyce

A1 - Brannigan,Maureen

A1 - Lafferty,Jane

A1 - Sproule,Michael

A1 - MacNee,William

A1 - Connell,Martin

A1 - Murchison,John T.

A1 - Shepherd,Malcolm C.

A1 - Feuerstein,Giora

A1 - Miller,Douglas K.

A1 - Thomson,Neil C.

AU - Chaudhuri,Rekha

AU - McSharry,Charles

AU - Brady,Jeffrey

AU - Donnelly,Iona

AU - Grierson,Christal

AU - McGuinness,Stephen

AU - Jolly,Lisa

AU - Weir,Christopher J.

AU - Messow,C. Martina

AU - Spears,Mark

AU - Miele,Gino

AU - Nocka,Karl

AU - Crowther,Dan

AU - Thompson,Joyce

AU - Brannigan,Maureen

AU - Lafferty,Jane

AU - Sproule,Michael

AU - MacNee,William

AU - Connell,Martin

AU - Murchison,John T.

AU - Shepherd,Malcolm C.

AU - Feuerstein,Giora

AU - Miller,Douglas K.

AU - Thomson,Neil C.

PY - 2012/3

Y1 - 2012/3

N2 - <p>Background: Matrix metalloproteinase (MMP)-12 has been implicated in the pathogenesis of both chronic obstructive pulmonary disease (COPD) and asthma. The influence of disease severity on sputum MMP-12 concentrations and activity is not known.</p><p>Objectives: We sought to examine the relationship between disease severity assessed by means of lung function and computed tomography (CT) and induced sputum MMP-12 concentrations and activity in patients with asthma and COPD. Methods: In 208 subjects (109 asthmatic patients, smokers and never smokers, mild, moderate, and severe; 53 patients with COPD, smokers and exsmokers, mild, moderate, and severe; and 46 healthy control subjects, smokers and never smokers), we measured induced sputum MMP-12 concentrations (ELISA) and enzyme activity (fluorescence resonance energy transfer), sputum cell MMP12 mRNA expression (quantitative PCR [qPCR]), diffusing capacity for carbon monoxide (DLCO), and CT assessment of emphysema (percentage of low-attenuation areas at less 2950 Hounsfield units).</p><p>Results: Sputum MMP-12 concentrations are greater in patients with COPD and smokers with asthma than in healthy nonsmokers (P = .003 and P = .035, respectively) but similar to those seen in healthy smokers. In patients with COPD, disease severity, when measured by means of CT-assessed emphysema, but not by means of spirometry or DLCO values, is directly associated with sputum MMP-12 concentrations and activity. In the asthma groups there is no significant association between disease severity and sputum MMP-12 concentrations or activity.</p><p>Conclusions: Sputum MMP-12 concentrations and activity in patients with COPD are directly associated with the extent of emphysema measured by means of CT. This finding supports a role for MMP-12 in the pathogenesis of COPD and might suggest that blocking MMP-12 activity in patients with COPD could prevent the further development of emphysema. (J Allergy Clin Immunol 2012; 129: 655-63.)</p>

AB - <p>Background: Matrix metalloproteinase (MMP)-12 has been implicated in the pathogenesis of both chronic obstructive pulmonary disease (COPD) and asthma. The influence of disease severity on sputum MMP-12 concentrations and activity is not known.</p><p>Objectives: We sought to examine the relationship between disease severity assessed by means of lung function and computed tomography (CT) and induced sputum MMP-12 concentrations and activity in patients with asthma and COPD. Methods: In 208 subjects (109 asthmatic patients, smokers and never smokers, mild, moderate, and severe; 53 patients with COPD, smokers and exsmokers, mild, moderate, and severe; and 46 healthy control subjects, smokers and never smokers), we measured induced sputum MMP-12 concentrations (ELISA) and enzyme activity (fluorescence resonance energy transfer), sputum cell MMP12 mRNA expression (quantitative PCR [qPCR]), diffusing capacity for carbon monoxide (DLCO), and CT assessment of emphysema (percentage of low-attenuation areas at less 2950 Hounsfield units).</p><p>Results: Sputum MMP-12 concentrations are greater in patients with COPD and smokers with asthma than in healthy nonsmokers (P = .003 and P = .035, respectively) but similar to those seen in healthy smokers. In patients with COPD, disease severity, when measured by means of CT-assessed emphysema, but not by means of spirometry or DLCO values, is directly associated with sputum MMP-12 concentrations and activity. In the asthma groups there is no significant association between disease severity and sputum MMP-12 concentrations or activity.</p><p>Conclusions: Sputum MMP-12 concentrations and activity in patients with COPD are directly associated with the extent of emphysema measured by means of CT. This finding supports a role for MMP-12 in the pathogenesis of COPD and might suggest that blocking MMP-12 activity in patients with COPD could prevent the further development of emphysema. (J Allergy Clin Immunol 2012; 129: 655-63.)</p>

U2 - 10.1016/j.jaci.2011.12.996

DO - 10.1016/j.jaci.2011.12.996

M1 - Article

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

VL - 129

SP - 655-U106

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy